CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 34 target
Drug / intervention
PD1/PDL1 antibody monotherapy, up to 24 weeks +2 moredrug
Likely dose
Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06580574
NCT06580574Phase 2RecruitingOn Track
CompareCT.gov

PD-1/PD-L1 Antibody With Selective Combination of Sintilimab, IBI310 and Lenvatinib Used for Organ Preservation in Non-metastatic Gastric or Colon Cancers With Mismatch Repair Deficiency or High Microsatellite Instability

Peking University·interventional·Posted Aug 30, 2024·Updated May 15, 2026

In Brief

A Phase 2 clinical trial evaluating PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, and 1 other intervention for Gastric Cancer and 3 related conditions. Currently recruiting, targeting 34 participants across 1 site.

Detailed Summary

This study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Colon Cancer, MSI-H, DMMR Cancer
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
20252026202720282029
First PostedAug 30, 2024
Enrollment StartSep 13, 2024
Primary CompletionJun 1, 2029
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 1.8 years agoPrimary completion in 2.9 years

Interventions

PD1/PDL1 antibody monotherapy, up to 24 weeksdrug

non-specific, according to Drug Instructions

Intensive immunotherapy plus anti-VEGF treatment, up to 24 weekscombination

Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd

Radical surgeryprocedure

Radical surgery will be recommended per local treatment standards.